Logo Logo
Hilfe
Hilfe
Switch Language to English

Szabados, Bernadett; Dijk, Nick van; Tang, Yen Zhi; Heijden, Michiel S. van der; Wimalasingham, Akhila; Liano, Alfonso Gomez de; Chowdhury, Simon; Hughes, Simon; Rudman, Sarah; Linch, Mark und Powles, Thomas (2018): Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer. In: European Urology, Bd. 73, Nr. 2: S. 149-152

Volltext auf 'Open Access LMU' nicht verfügbar.

Abstract

Immune checkpoint inhibitors (ICIs) are active in metastatic urothelial carcinoma (MUC). They have joined chemotherapy (CT) as a standard of care. Here, we investigate the activity of CT after progression on ICIs. Two cohorts of sequential patients with MUC were described (n = 28). Cohort A received first-line ICIs followed by CT after progression. Cohort B received CT after failure of first-line platinum-based CT followed by ICIs. Response rate (RR) to CT was assessed using Response Evaluation Criteria in Solid Tumors (RECIST v1.1) by a designated radiologist. Best RR for cohort A was 64%. Two patients experienced clinical progression and died before the first radiographic assessment. RR for cohort B was 21%, which was significantly lower than that for cohort A. Progression of disease occurred in 43% of cohort B patients by the end of CT. These data suggest a lack of cross resistance between CT and ICIs in MUC. Therefore, the sequencing of these drugs is likely to be important to maximise outcomes. This is particularly true after first-line ICIs as subsequent CT has significant activity. Patient summary: In this report, we studied the effect of chemotherapy in metastatic bladder cancer, which relapsed after immune checkpoint inhibitors. We found that the activity of chemotherapywas maintained despite previous exposure to immune therapy. This underlines the importance of sequencing these agents to maximise outcomes.

Dokument bearbeiten Dokument bearbeiten